|
Indications And Usage Paclitaxel Injection Is Indicated As Subsequent Therapy For The Treatment Of Advanced Carcinoma Of The Ovary. As First-Line Therapy, Paclitaxel Injection Is Indicated In Combination With Cisplatin. Paclitaxel Injection Is Indicated For The Adjuvant Treatment Of Node-Positive Breast Cancer Administered Sequentially To Standard Doxorubicin-Containing Combination Chemotherapy. In The Clinical Trial, There Was An Overall Favorable Effect On Disease-Free And Overall Survival In The Total Population Of Patients With Receptor-Positive And Receptor-Negative Tumors, But The Benefit Has Been Specifically Demonstrated By Available Data (Median Follow-Up 30 Months) Only In The Patients With Estrogen And Progesterone Receptor-Negative Tumors (See Clinical Studies, Breast Carcinoma ). Paclitaxel Injection Is Indicated For The Treatment Of Breast Cancer After Failure Of Combination Chemotherapy For Metastatic Disease Or Relapse Within 6 Months Of Adjuvant Chemotherapy. Prior Therapy Should Have Included An Anthracycline Unless Clinically Contraindicated. Paclitaxel Injection, In Combination With Cisplatin, Is Indicated For The First-Line Treatment Of Non-Small Cell Lung Cancer In Patients Who Are Not Candidates For Potentially Curative Surgery And/or Radiation Therapy. Paclitaxel Injection Is Indicated For The Second-Line Treatment Of Aids-Related Kaposi’s Sarcoma.
|